Biological Substrates of Impaired Neurocognitive Functioning: Understanding the Late Effects of Surviving a Pediatric Brain Tumor
- Children’s Medical Center (Dallas, Plano, Southlake)
Nancy Rollins, M.D.
Survivors of pediatric brain tumors commonly struggle with progressive declines in attention and memory that emerge following neurosurgery, chemotherapy and radiation. unfortunately, little is known about the neurobiological substrates of these cognitive dysfunctions. Consequently, the aim of this study is to identify the specific changes in functional and structural brain connectivity that correlate with neurocognitive decline by collecting advanced magnetic resonance imaging (MRi) and neuropsychological test data on Survivors of pediatric benign and malignant posterior fossa brain tumors and comparing them with healthy controls across 4 academic medical centers: Memorial Sloan Kettering Cancer Center, Columbia university Medical Center, Children's Health System Dallas and Seattle Children's Hospital.
Inclusion Criteria for Children Treated for Posterior Fossa Tumors:
1. Successfully completed all medical treatment for either an M0 posterior fossa medulloblastoma without dissemination or posterior fossa low-grade astrocytoma without relapse or evidence of residual disease.
2. Medulloblastoma survivors should have been previously treated with gross total resection, craniospinal irradiation with conformal posterior fossa boost radiotherapy and chemotherapy; whereas, low grade astrocytoma survivors should have been treated with gross total resection only and no chemotherapy or radiotherapy.
3. Subjects are between 1-4 years post completion of their medical treatment for their posterior fossa brain tumor and between the ages of 6 through 16 years at time of consent.
Inclusion Criteria for Healthy Control Participants:
1. No major medical illness, as determined by medical interview by study physician.
2. Subject is currently between the ages of 6-16 years of age.